Matthew Sims

Photo Quiz: A camper with fever, headache, and fatigue

Benjamin von Bredow, Matthew Sims, Bobby L. Boyanton

us (code pays fourni par la source)

Interpretability of an FDA-authorized AI/ML sepsis diagnostic tool improved by SHAP values

Gregory L. Watson, Grace L. Staples, Robin Carver, Akhil Bhargava et autres

Objectives: To assess the interpretability and acceptance of Shapley values for making artificial intelligence/machine learning (AI/ML) tools more transparent, interpretable, and useful to clinicians. Materials and Methods: Structured assessments were conducted with 30 clinicians (15 providers; 15 nurses; 8 assessments per clinician) …

us (code pays fourni par la source)

Opportunities for RNA sequencing in physiology: from big data to understanding homeostasis and heterogeneity

Jeremy W. Prokop, Stephanie M. Bilinovich, Sangeetha Vishweswaraiah, Sophie Vanderweele et autres

The quantity of physiological data has grown exponentially, yielding insights into mechanisms of phenotypic and disease pathways. Among the powerful tools for physiological omics is the study of RNA, where broad sequencing of RNA leads to hypothesis generation and testing while providing …

us (code pays fourni par la source)

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia

Nicholas Turner, Toshimitsu Hamasaki, Sarah B. Doernberg, Thomas P. Lodise et autres

Importance: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access. Objective: To evaluate the efficacy and safety of dalbavancin vs standard therapy for completion of treatment of complicated S …

us, fr, ca (code pays fourni par la source)

P-1573. Methenamine Prophylaxis for Recurrent Urinary Tract Infections

Hani Salwan AL, Matthew Sims

Abstract Background Urinary tract infections (UTIs) are the most common outpatient infection in the United States. Between 50%-60% of women will experience at least one UTI during their life and women over 65 experience UTIs at twice the rate of women overall. …

us (code pays fourni par la source)

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas Louie et autres

us, ca (code pays fourni par la source)

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie et autres

INTRODUCTION: Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics for rCDI. OBJECTIVE, DESIGN, AND PATIENTS: To evaluate safety and efficacy of …

us, ca (code pays fourni par la source)